Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1

Biochemical Journal

Volumn 373, Issue 3, 2003, Pages 723-732

  Einholm, Anja P ^a   Pedersen, Katrine E ^a   Wind, Troels ^a   Kulig, Paulina ^a   Overgaard, Michael T ^a   Jensen, Jan K ^a   BØdker, Julie S ^a   Christensen, Anni ^a   Charlton, Peter ^b   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b Xenova   (United Kingdom)

Author keywords

Cancer; Protease; Serpin; Therapeutic target; Thrombosis

Indexed keywords

AROMATIC HYDROCARBONS; CHEMICAL BONDS; CONFORMATIONS; DISEASES; MOLECULAR STRUCTURE;

PLASMINOGEN;

BIOCHEMISTRY;

PIPERAZINEDIONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; SERINE PROTEINASE INHIBITOR; XR 5118;

ARTICLE; BINDING AFFINITY; CANCER; CARDIOVASCULAR DISEASE; CHEMICAL BOND; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVE SITE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING;

HUMANS; HYDROLYSIS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PIPERAZINES; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

INSERTION SEQUENCES;

EID: 0042697195     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20021880     Document Type: Article

References (49)

1. Andreasen, P. A., Egelund, R. and Petersen, H. H. (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57, 25-40
2. Booth, N. A. (1999) Fibrinolysis and thrombosis. Baillieres Best Pract. Res. Clin. Haematol. 12, 423-433
3. Erickson, L. A., Fici, G. J., Lund, J. E., Boyle, T. P., Polites, H. G. and Marotti, K. R. (1990) Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature (London) 346, 74-76
4. Eren, M., Painter, C. A., Atkinson, J. B., Declerck, P. J. and Vaughan, D. E. (2002) Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106, 491-496
5. Huber, K., Christ, G., Wojta, J. and Gulba, D. (2001) Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb. Res. 103 (Suppl. 1), 7-19
6. Andreasen, P. A., Kjøller, L., Christensen, L. and Dully, M. J. (1997) The urokinase-type plasminogen activator system in cancer metastasis A review. Int. J. Cancer 72, 1-22
7. Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brünner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D. et al. (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4, 923-928
8. Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brünner, N., Danø, K. et al. (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 152, 777-784
9. Lambert, V., Munaut, C., Noel, A., Frankenne, F., Bajou, K., Gerard, R., Carmeliet, P., Defresne, M. P., Foidart, J. M. and Rakic, J. M. (2001) Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 15, 1021-1027
10. McMahon, G. A., Petitclerc, E., Stefansson, S., Smith, E., Wong, M. K., Westrick, R. J., Ginsburg, D., Brooks, P. C. and Lawrence, D. A. (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276, 33964-33968
11. Devy, L., Blacher, S., Grignet-Debrus, C., Bajou, K., Masson, V., Gerard, R. D., Gils, A., Carmeliet, G., Carmeliet, P., Declerck, P. J. et al. (2002) The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 16, 147-154
12. Irving, J. A., Pike, R. N., Lesk, A. M. and Whisstock, J. C. (2000) Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res. 10, 1845-1864
13. Wind, T., Hansen, M., Jensen, J. K. and Andreasen, P. A. (2002) The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor-1: roles of the reactive centre loop, the shutter region, the flexible joint region, and the small serpin fragment. Biol. Chem. 283, 21-36
14. Shore, J. D., Day, D. E., Francis-Chmura, A. M., Verhamme, I. M., Kvassman, J., Lawrence, D. A. and Ginsburg, D. (1995) A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J. Biol. Chem. 270, 5395-5398
15. Lawrence, D. A., Ginsburg, D., Day, D. E., Berkenpas, M. B., Verhamme, I. M., Kvassman, J. O. and Shore, J. B. (1995) Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J. Biol Chem. 270, 25309-25312
16. Wilczynska, M., Fa, M, Ohlsson, P. I. and Ny, T. (1995) The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor comprex. J. Biol. Chem. 270, 29652-29655
17. Egelund, R., Rodenburg, K. W., Andreasen, P. A., Rasmussen, M. S., Guldberg, R. E. and Petersen, T. E. (1998) An ester bond linking a fragment of a serine protease to its serpin inhibitor. Biochemistry 37, 6375-6379
18. Stratikos, E. and Gettins, P. G. (1999) Formation of the covalent serpin-protease complex involves translocation of the protease by more than 70 Å and full insertion of the reactive center loop into β-sheet A. Proc. Natl. Acad. Sci. U.S.A. 96, 4808-4813
19. Fa, M., Bergström, F., Hägglöf, P., Wilczynska, M., Johansson, L. B.-Å. and Ny, T. (2000) The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites. Structure 8, 397-405
20. Huntington, J. A., Read, R. J. and Carrell, R. W. (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature (London) 407, 923-926
21. Egelund, R., Petersen, T. E. and Andreasen, P. A. (2001) A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the protease substrate binding pocket and oxyanion hole in the serpin inhibitory mechanism. Eur. J. Biochem 268, 673-685
22. Ye, S., Cech, A. L., Belmares, R., Bergstrom, R. C., Tong, Y., Corey, D. R., Kanost, M. R. and Goldsmith, E. J. (2001) The structure of a Michaelis serpin-protease complex. Nat. Struct. Biol. 8, 979-883
23. Mottonen, J., Strand, A., Symersky, J., Sweet, R. M., Danley, D. E., Geoghegan, K. F., Gerard, R. D. and Goldsmith, E. J. (1992) Structural basis of latency in plasminogen activator inhibitor-1. Nature (London) 355, 270-273
24. Sharp, A. M., Stein, P. E., Pannu, N. S., Carrell, R. W., Berkenpas, M. B., Ginsburg, D., Lawrence, D. A. and Read, R. J. (1999) The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 7, 111-118
25. Nar, H., Bauer, M., Stassen, J. M., Lang, D., Gils, A. and Declerck, P. J. (2000) Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J. Mol. Biol. 297, 683-695
26. Egelund, R., Einholm, A. P., Pedersen, K. E., Niersen, R. W., Christensen, A., Deinum, J. and Andreasen, P. A. (2001) A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands. Ligand-induced serpin polymerization. J. Biol. Chem. 276, 13077-13086
27. Charlton, P. A., Faint, R. W., Bent, F., Bryans, J., Chicarelli-Robinson, I., Mackie, I, Machin, S. and Bevan, P. (1996) Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb. Haemost. 75, 808-815
28. Friederich, P. W., Levi, M., Biemond, B. J., Charlton, P., Templeton, D., van Zonneveld, A. J., Bevan, P., Pannekoek, H. and ten Cate, J. W. (1997) Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces post thrombolysis thrombus growth in rabbits. Circulation 96, 916-921
29. Björquist, P., Ehnebom, J., Inghardt, T., Hansson, L., Lindberg, M., Linschoten, M., Stromqvist, M. and Deinum, J. (1998) Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. Biochemistry 37, 1227-1234
30. Neve, J., Leone, P. A., Carroll, A. R., Moni, R. W., Paczkowski, N. J., Pierens, G., Björquist, P., Deinum, J., Ehnebom, J. and Inghardt, T. (1999) Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. J. Nat. Prod. 62, 324-326
31. Gils, A., Stassen, J.-M., Nar, H., Kley, J. T., Wienen, W., Ries, U. J. and Declerck, P. J. (2002) Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb. Haemost. 88, 137-143
32. Christensen, J. H., Hansen, P. K., Lillelund, O. and Thøgersen, H. C. (1991) Sequence-specific binding of the N-terminal three-finger fragment of Xenopus transcription factor IIIa to the internal control region of a 5 S RNA gene. FEBS Lett. 281, 181-184
33. Gill, S. C. and von Hippel, P. H. (1989) Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182, 319-326
34. Jensen, J. K., Wind, T. and Andreasen, P. A. (2002) The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand. FEBS Lett. 521, 91-94
35. Wind, T., Jensen, M. A. and Andreasen, P. A. (2001) Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1. Implications for antibody-mediated PAI-1 neutralisation and vitronectin binding. Eur. J. Biochem. 268, 1095-1106
36. Egelund, R., Schousboe, S. L., Sottrup-Jensen, L., Rodenburg, K. W. and Andreasen, P. A. (1997) Type-1 plasminogen activator inhibitor. Conformational differences between latent, active, reactive-center-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur. J. Biochem. 248, 775-785
37. Andreasen, P. A., Riccio, A., Welinder, K. G., Douglas, R., Sartorio, R., Nielsen, L. S., Oppenheimer, C., Blasi, F. and Danø, K. (1986) Plasminogen activator inhibitor type 1: reactive center and amino-terminal heterogeneity, determined by protein and cDNA sequencing. FEBS Lett. 209, 213-218
38. Lovrien, R. and Matulis, D. (1995) Assays for total protein. In Current Protocols in Protein Science (Coligan, J. E., Dunn, B. M., Ploegh, H. L., Speicher, D. W. and Wingfierd, P. T., eds.), John Wiley and Sons, New York
39. Schägger, H. and von Jagow, G. (1991) Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal. Biochem. 199, 223-231
40. Gils, A. and Declerck, P. J. (1998) Modulation of plasminogen activator inhibitor 1 by Triton X-100-identification of two consecutive conformational transitions. Thromb. Haemost. 80, 286-291
41. Kjøller, L., Martensen, P. M., Sottrup-Jensen, L., Justesen, J., Rodenburg, K. W. and Andreasen, P. A. (1996) Conformational changes of the reactive-centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1. Eur. J. Biochem. 241, 38-46
42. Andreasen, P. A., Egelund, R., Jensen, S. and Rodenburg, K. W. (1999) Solvent effects on activity and conformation of plasminogen activator inhibitor-1. Thromb. Haemost. 81, 407-414
43. Zhou, A., Faint, R., Charlton, P., Dafforn, T. R., Carrell, R. W. and Lomas, D. A. (2001) Polymerization of plasminogen activator inhibitor-1. J. Biol. Chem. 276, 9115-9122
44. Berkenpas, M. B., Lawrence, D. A. and Ginsburg, D (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14, 2969-2977
45. Wind, T., Jensen, J. K., Dupont, D. M. and Andreasen, P. A. (2003) Mutational analysis of plasminogen activator inhibitor-1. Eur. J. Biochem. 270, 1680-1688
46. Cabrita, L. D., Whisstock, J. C. and Bottomley, S. P. (2002) Probing the role of the F-helix in serpin stability through a single tryptophan substitution. Biochemistry 41, 4575-4581
47. Schousboe, S. L., Egelund, R., Kirkegaard, T., Preissner, K. T., Rodenburg, K. W. and Andreasen, P. A. (2000) Vitronectin and substitution of a β-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against α-helix F. Thromb. Haemost. 83, 742-751
48. Hansen, M., Busse, M. N. and Andreasen, P. A. (2001) Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms. Eur. J. Biochem. 268, 6274-6283
49. Jensen, S., Kirkegaard, T., Pedersen, K. E., Busse, M., Preissner, K. T., Rodenburg, K. W. and Andreasen, P. A. (2002) The role of β-strand 5A residues of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin. Biochim. Biophys. Acta 1597, 301-310